MeiraGTx saw the highest growth of 2.59% in patent filings and 0.66% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 2.59% and grants by 0.66%. GlobalData’s DataBook provides a comprehensive analysis of MeiraGTx‘s patent filings and grants. Buy the databook here.
MeiraGTx has been focused on protecting inventions in World Intellectual Property Organization(WIPO) with 11 publications in Q2 2024
The World Intellectual Property Organization(WIPO) Patent Office dominates the patent filings with nearly 58% of filings. The World Intellectual Property Organization(WIPO), European Patent Office(EPO), South Korea(KR), and United States(US) patent Office are among the top ten patent offices where MeiraGTx is filings its patents. Among the top granted patent authorities, MeiraGTx has 25% of its grants in Australia(AU).
University of Pennsylvania could be the strongest competitor for MeiraGTx
Patents related to cell & gene therapy and rare diseases lead MeiraGTx's portfolio
MeiraGTx has the highest number of patents in cell & gene therapy followed by, rare diseases. For cell & gene therapy, nearly 90% of patents were filed and no patents were granted in Q2 2024.
Drug delivery devices related patents lead MeiraGTx portfolio followed by obesity
MeiraGTx has highest number of patents in drug delivery devices followed by obesity.
For comprehensive analysis of MeiraGTx's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.